433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial...

by Min Yi, Celeste Lebbe, Parminder Singh, Omid Hamid, Jason Chesney, Igor Puzanov, Mohammed Milhem, Merrick Ross, Janice Mehnert, Theodore Logan, Philip Friedlander, Frances Collichio, Claus Garbe, John Glaspy, Axel Hauschild, Wendy Snyder
Published 2020-11-01

194 A multicenter characterization of chronic toxicities following adjuvant anti-PD-1 therapy for high risk resected melanoma

by Andrew Haydon, Rebecca Johnson, Iman Osman, Janice Mehnert, Suthee Rapisuwon, Douglas Johnson, Ryan Sullivan, Matteo Carlino, Alexander Menzies, Prachi Bhave, James Patrinely, Aleigha Lawless, Amelia Sawyers, Maya Dimitrova, Hui Yeohc, Marisa Palmeri, Elizabeth Davis, Georgina Long
Published 2020-11-01

Clinical characterization of colitis arising from anti-PD-1 based therapy

by Daniel Y Wang, Meghan J Mooradian, DaeWon Kim, Neil J Shah, Sarah E Fenton, Robert M Conry, Rutika Mehta, Ann W. Silk, Alice Zhou, Margaret L Compton, Rami N Al-Rohil, Sunyoung Lee, Amber L Voorhees, Lisa Ha, Svetlana McKee, Jacqueline T Norrell, Janice Mehnert, Igor Puzanov, Jeffrey A Sosman, Sunandana Chandra, Geoffrey T Gibney, Suthee Rapisuwon, Zeynep Eroglu, Ryan Sullivan, Douglas B Johnson
Published 2019-01-01